Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005892|
Recruitment Status : Completed
First Posted : June 5, 2000
Last Update Posted : June 24, 2005
I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with myelodysplastic syndrome and acute leukemia related to Fanconi's anemia.
|Condition or disease||Intervention/treatment||Phase|
|Fanconi's Anemia Myelodysplastic Syndromes Leukemia, Nonlymphocytic, Acute Leukemia, Lymphocytic, Acute||Drug: cyclophosphamide Procedure: Allogeneic Bone Marrow Transplantation||Not Applicable|
Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||March 2000|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005892
|United States, Minnesota|
|Fairview University Medical Center|
|Minneapolis, Minnesota, United States, 55455|
|Study Chair:||Daniel J. Weisdorf||Fairview University Medical Center|